Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Current Deferred Revenue (2016 - 2024)

Historic Current Deferred Revenue for Rhythm Pharmaceuticals (RYTM) over the last 7 years, with Q4 2024 value amounting to $1.3 million.

  • Rhythm Pharmaceuticals' Current Deferred Revenue changed 0.0% to $1.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.3 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $1.3 million for FY2024, which is 0.0% changed from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Current Deferred Revenue stood at $1.3 million for Q4 2024, which was down 0.0% from $1.3 million recorded in Q3 2024.
  • Rhythm Pharmaceuticals' 5-year Current Deferred Revenue high stood at $9.4 million for Q1 2022, and its period low was $1.3 million during Q2 2023.
  • For the 4-year period, Rhythm Pharmaceuticals' Current Deferred Revenue averaged around $2.5 million, with its median value being $1.3 million (2023).
  • In the last 5 years, Rhythm Pharmaceuticals' Current Deferred Revenue tumbled by 8487.29% in 2023 and then changed by 0.0% in 2024.
  • Over the past 4 years, Rhythm Pharmaceuticals' Current Deferred Revenue (Quarter) stood at $7.0 million in 2021, then tumbled by 79.51% to $1.4 million in 2022, then dropped by 10.32% to $1.3 million in 2023, then changed by 0.0% to $1.3 million in 2024.
  • Its last three reported values are $1.3 million in Q4 2024, $1.3 million for Q3 2024, and $1.3 million during Q2 2024.